NCT00691015 · OUTCOME

Incidence of Acute Graft-versus-host Disease (GVHD)

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant · Source last updated 2017-06-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: 90% Confidence Interval
Time frame: Within 100 days after donor peripheral blood stem cell transplantation (PBSCT) as assessed by Glucksberg criteria

Groups in this outcome

All Participants

All regimens were analyzed together.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Participants	47

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: 90% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
All Participants	44.7	Not reported	33.4	56.6	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
33.4
upper Limit
56.6
value
44.7

denoms

counts
group Id
OG000
value
47
units
Participants

dispersion Type

90% Confidence Interval

groups

description
All regimens were analyzed together.
id
OG000
title
All Participants

param Type

NUMBER

reporting Status

POSTED

time Frame

Within 100 days after donor peripheral blood stem cell transplantation (PBSCT) as assessed by Glucksberg criteria

title

Incidence of Acute Graft-versus-host Disease (GVHD)

type

PRIMARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice